Abstract
Current standard cancer therapies (chemotherapy and radiation) often cause serious adverse off-target effects. Drug design strategies are therefore being developed that will more precisely target cancer cells for destruction while leaving surrounding normal cells relatively unaffected. Telomerase, widely expressed in most human cancers but almost undetectable in normal somatic cells, provides an exciting drug target. This review focuses on recent pharmacogenomic approaches to telomerase inhibition. Antisense oligonucleotides, RNA interference, ribozymes, mutant expression, and the exploitation of differential telomerase expression as a strategy for targeted oncolysis are discussed here in the context of cancer therapeutics. Reports of synergism between telomerase inhibitors and traditional cancer therapeutic agents are also analyzed.
Keywords: Telomerase inhibition, hTR, hTERT, antisense, RNAi, ribozyme, dominant-negative hTERT, mutant-template telomerase RNA
Current Medicinal Chemistry
Title: Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Volume: 13 Issue: 24
Keywords: Telomerase inhibition, hTR, hTERT, antisense, RNAi, ribozyme, dominant-negative hTERT, mutant-template telomerase RNA
Abstract: Current standard cancer therapies (chemotherapy and radiation) often cause serious adverse off-target effects. Drug design strategies are therefore being developed that will more precisely target cancer cells for destruction while leaving surrounding normal cells relatively unaffected. Telomerase, widely expressed in most human cancers but almost undetectable in normal somatic cells, provides an exciting drug target. This review focuses on recent pharmacogenomic approaches to telomerase inhibition. Antisense oligonucleotides, RNA interference, ribozymes, mutant expression, and the exploitation of differential telomerase expression as a strategy for targeted oncolysis are discussed here in the context of cancer therapeutics. Reports of synergism between telomerase inhibitors and traditional cancer therapeutic agents are also analyzed.
Export Options
About this article
Cite this article as:
Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches, Current Medicinal Chemistry 2006; 13 (24) . https://dx.doi.org/10.2174/092986706778521887
DOI https://dx.doi.org/10.2174/092986706778521887 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Chemotherapy for Laryngeal Cancer - An Apoptotic Approach
Current Drug Targets Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
Current Drug Targets The DNA-Binding and Bioactivity of Rare Earth Metal Complexes
Mini-Reviews in Medicinal Chemistry Molecular and Genetic Bases of Pancreatic Cancer
Current Drug Targets New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. Current Perspectives and Novel Strategies
Recent Patents on Biomarkers Tyrosine Kinase Inhibitors
Current Cancer Drug Targets The DNA Methylation Machinery as a Therapeutic Target
Current Drug Targets Sentinel Node Imaging
Current Medical Imaging Heat Shock Protein 70s as Potential Molecular Targets for Colon Cancer Therapeutics
Current Medicinal Chemistry The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Tea (Camellia sinensis (L.)): A Putative Anticancer Agent in Bladder Carcinoma?
Anti-Cancer Agents in Medicinal Chemistry Cell Death in Mammalian Development
Current Pharmaceutical Design Oxidative DNA Damage and Oxidant/Anti-Oxidant Enzymatic Systems in Carcinogenesis and Cancer Progression
Current Enzyme Inhibition Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Current Drug Targets Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews